Analysis of Drug-Induced Liver Injury the Last Ten Years in the Department of Gastroenterology

Makoto Irie, Hideo Kunimoto, Atsushi Fukunaga, Kaoru Yotsumoto, Shizuka Kuno, Kunitoshi Sakurai, Hideyuki Iwashita, Genryu Hirano, Shu-ichi Ueda, Keiji Yokoyama, Daisuke Morihara, Shinya Nishizawa, Akira Anan, Yasuaki Такеуама, Masaharu Sakamoto, Kaoru Iwata, Satoshi Shakado, Tetsuro Sohda, and Shotaro Sakisaka

Department of Gastroenterology, Faculty of Medicine, Fukuoka University.

Abstract: The study investigated the occurrence and reviewed the characteristics of 132 patients with drug-induced liver injury over ten years from the outpatient ward of this department. The average age was 57.6 ± 15.2 years old. Forty-eight (36.4%) of the cases had an alcohol history. In addition, 66.7% of the patients were taking more than two drugs for an underlying disease. The drug-induced liver injury was the hepatocellular type in 44.7% of cases and of cholestasis type in 9.8% of cases. The mixed type was prevalent, accounting for 45.5%. The positive rate of drug-induced lymphocyte stimulation test (DLST) was 36.8% and the eosinophilia rate (more than 6%) was 25.2%. Many cases were diagnosed as "highly probable" under the scoring for drug-induced liver injury. The main causal drugs were anti-infectious drugs (12.5%), anti-inflammatory drugs (9.8%), and dietary supplements (9.4%). There was no singular timeline regarding the manifestation of liver damage. All cases recovered with the discontinuation of the causative medications or with the introduction of pharmacotherapy. Anti-infectious agents were the main causal drugs. The study also highlights the risks involved in the easy consumption of unproved dietary supplements.

Key words: Drug-induced liver injury, Diagnostic scale, Drug-induced lymphocyte stimulation test (DLST), Eosinophilia